A Study Assessing The Effects Of Fingolimod On Cardiovascular Autonomic Modulation (CAM) In Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) After Two Years Of Continuous Daily Therapy

Trial Profile

A Study Assessing The Effects Of Fingolimod On Cardiovascular Autonomic Modulation (CAM) In Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) After Two Years Of Continuous Daily Therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 May 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 05 May 2017 New trial record
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top